Turkey’s $2.6Bn Hospital Medtech Debts Create Problems On Top Of COVID-19
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
You may also be interested in...
A plan to set up a Directorate of Health Industries within the Office of the Presidency has been welcomed by Turkish medtechs, who see it as opportunity to highlight to President Erdoğan ongoing industry problems such as late payments.
Late payment of hospital debts continues to haunt the Turkish medtech industry, which recently led a public demonstration in Ankara to focus the government’s attention on the issue. Medtech multinationals fear that the ongoing problems will mean Turkey losing the positive momentum it achieved during the pandemic.
One Hurdle After Another: Safely Aligned With EU MDR, Turkish Medtechs Brace For New Efforts On Domestic Front
Alignment with the MDR gave Turkish medtech access to the EU market, but in domestic pricing, costs, reimbursement and payment of hospital debts, industry might feel it is barely at the starting line.